Sandoz receives Health Canada approval for Jubbonti

Sandoz Canada announces that Health Canada has provided authorization to market Jubbonti. “Denosumab is an important biologic therapy used by more than 500,000 patients in Canada. As a pioneer in patient access, we take great pride in being the first company to introduce and bring to the Canadian market a denosumab biosimilar in the field of immunology.” – Michel Robidoux, President and General Manager, Sandoz Canada